Drug Insights

Master Morphine Search on Synapse

18 March 2024
2 min read

Morphine Sulfate, an exceptional and potent drug, selectively targets opioid receptors in the body, providing unsurpassed relief from pain and its associated effects. As an agonist, it stimulates mu, kappa, and delta opioid receptors, binding and activating these specific receptors, and serving as an impeccable option for managing severe pain, such as that resulting from cancer or post-surgery. The drug underwent extensive regulatory scrutiny and was granted approval in September 1984. Since then, it has become a widely used and trusted means of pain management, despite being a controlled substance that requires prescriptions from healthcare providers due to its potential for abuse and addiction. Patients should be mindful of the range of potential side effects associated with Morphine Sulfate, including dizziness, nausea, constipation, respiratory depression, among others. Hence, it is of utmost importance for patients to be well-informed about the risks associated with its use and adhere to their healthcare provider's guidance meticulously. Click on the image below to begin the exploration journey of Morphine through the Synapse database!

图形用户界面, 文本, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Promising Phase 2 Results for Ionis's ION224 in NASH/MASH Treatment
Latest Hotspot
3 min read
Promising Phase 2 Results for Ionis's ION224 in NASH/MASH Treatment
18 March 2024
Ionis has disclosed encouraging outcomes from its second-phase trial of ION224, a drug currently being tested which shows promise in addressing NASH/MASH conditions.
Read →
Unveiling Pseudoephedrine: How to Search for it on Synapse
Drug Insights
2 min read
Unveiling Pseudoephedrine: How to Search for it on Synapse
18 March 2024
Pseudoephedrine Hydrochloride, a small molecule drug, acts as an α-adrenergic receptor agonist, exerting its effects through the stimulation of α-adrenergic receptors.
Read →
Silence Therapeutics' Zerlasiran Shows Promise in Phase 2 Trial for High Lipoprotein(a)
Latest Hotspot
3 min read
Silence Therapeutics' Zerlasiran Shows Promise in Phase 2 Trial for High Lipoprotein(a)
15 March 2024
Silence Therapeutics Reveals Encouraging Preliminary Results at 36 Weeks from Active Phase 2 Trial with Zerlasiran in Subjects with Elevated Lipoprotein(a) Levels.
Read →
Development of CCR8 Antibodies as a Hot Target for Immuno-Oncology Therapy in Solid Tumors
Development of CCR8 Antibodies as a Hot Target for Immuno-Oncology Therapy in Solid Tumors
15 March 2024
Deciphering CCR8 Activation and Inhibition Mechanisms: Genentech's Findings in Nature Communications.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.